polit volatil continu biotech index move mere
week realli feel way whipsaw drug price propos
domin investor convers see note senat
bill potenti execut order overal investor
agre predict outcom difficult progress senat bill
coupl administr support investor believ part
 oral oncolog drug risk risk relat may
lessen remind highlight part part exposur
compani see next week bring
compani news week announc ceo transit
surpris mani said appear orderli transit occur
month management indic us current ceo leiden remain
involv compani focu busi develop build-out
gene edit site investor polit outreach earn
focu achiev beat
stock outcom differ believ low qualiti beat
reward given generalist audienc high qualiti
beat sold investor worri next catalyst around eu ip
term key research week focus upcom readout
lead compound see import
outcom signal would highlight compound studi
mild/moder patient ahead biolog investor expect
limit clinic respons especi day also continu receiv
signific feedback bgne note bear necessarili focus
zanubrutinib wm view china oncolog market
opportun bgne limit bull believ would also highlight
climat chang report issu collabor esg colleagu
potenti need vaccin topic diseas
prescript data biktarvi wk/wk
tymlo share anabol market aimovig
wk/wk repres market competitor teva
market share flat market share flat lilli
teva cover david rising
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
week mostli earn plu asr data asr
saturday slide post main focu remain efficaci
durabl open-label studi continu believ result
direct support earn believ investor focus
tuesday expect beat see
risk see preview
top question includ larg cap bear
skeptic updat bull see data larg support
upcom mdd studi bull bear remain polar view
focus potenti fda panel follow file larg cap drug
price remain key focu mainli investor apathi toward group
final impact daiichi remain key debat
price target base dcf use discount rate
termin growth rate post flow base explicit revenu project
current primari revenu driver vrtx cystic fibrosi therapi
kalydeco orkambi us ex-u futur growth expect primarili
triplet therapi risk includ combo penetr fall short
expect kalydeco sale fail meet expect data
competit exce expect
price target base dcf model use discount rate
termin growth rate follow model base
explicit revenu project primari revenu driver model alexion key
franchis soliri pnh ahu mg current indic expect nmo
begin contribut revenu also model explicit revenu strensiq
global launch kanuma launch lal-d risk includ soliri pnh
ahu growth expect inabl obtain approv nmo weak
launch strensiq kanuma soliri mg
price target base dcf model discount rate base
busi valu compris revenu project key in-line drug tysabri
tecfidera avonex/plegridi rituxan spinraza risk slowdown
base busi pipelin failur greater competition/pr pressur base
busi alreadi contempl model
deriv pt discount cash flow analysi assum wacc
termin growth rate revenu driver model evelo lead
monoclon microbi product candid atop dermat
psoriasi risk includ earli setback microbiom focus compani
weigh investor percept safeti efficaci lead develop program
remain unclear therefor risk initi clinic readout could beli
expect investor may write entir evelo platform earli data
readout meet investor expect
bgne price target base dcf use discount rate
termin growth rate explicit revenu project revenu
project incorpor china ex-china sale beigen four key product
inhibitor antibodi well celgen commerci oper
china risk includ inadequ efficaci and/or safeti data on-going clinic
trial inabl demonstr superior compet compound regulatori
chang china compromis access chines market beigen prefer
pt base dcf use discount rate model explicit
revenu valu growth beyond project revenu
lead product candid wet diabet eye diseas project
revenu begin grow
risk includ lack fda approv poor safeti and/or durabl data
lead investor question compani lead asset platform strong
competitor data prior meaning dataset releas kodiak inferior
efficaci compar standard care
price target base dcf model use discount rate
termin growth rate onward model base explicit
revenu project current revenu driver neulasta enbrel epogen
aranesp cholesterol lower drug repatha pipelin drive revenu
growth throughout project period pipelin driver includ aimovig
migrain develop biosimilar risk includ biosimilar competit
base busi neulasta enbrel failur pipelin asset
price target base dcf use discount rate
termin growth rate model explicit product revenu bulk
gilead revenu deriv antivir product compris gilead
hepat hcv hiv franchis hcv revenu driver harvoni sovaldi epclusa
vosevi hiv product includ atripla truvada viread stribild taf-bas
regimen key non antivir product axi-cel blood cancer risk includ
deceler growth hcv sale volatil hiv franchis poor axi-cel launch
pipelin failur
price target base dcf use discount rate
termin growth rate onward model explicit revenu gbt late-
stage oral sickl cell diseas therapi voxelotor launch model
risk includ clinical/regulatori failur voxelotor safeti relat advers
event greater expect uptak compet gene therapi treatment low
patient complianc high discount due signific medicaid popul drive
product revenu
pt deriv dcf use discount rate
termin growth rate beyond valu neurolog program
assum brexanolon launch provid bulk valuat
launch mdd bipoloar insomnia risk price
target includ failur brexanolon receiv regulatori approv limit
uptak due gener competit unexpect safeti risk sage-
pt base dcf use discount rate project free cash
flow base termin valu onward use
termin growth rate project revenu lead product candid
tnbc muc risk-adjust basi risk includ lack fda
approv poor penetr key launch market lack label expans
earlier line therapi tumor type
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import us regulatori disclosur subject compani
june benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur alector inc argenx se avrobio inc
within last month receiv compens invest bank servic alector inc argenx se avrobio inc
next month expect receiv intend seek compens invest bank servic akebia
within last month receiv compens product servic invest bank servic amgen inc
within last month provid provid invest bank servic invest bank client relationship
follow compani alder biopharmaceut inc alector inc alnylam
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani amgen inc beigen ltd biogen inc biomarin
 co llc make market secur alder biopharmaceut inc alector inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
use rel rate system use term overweight equal-weight not-rat underweight see definit morgan
stanley assign rate buy hold sell stock cover overweight equal-weight not-rat underweight equival
buy hold sell investor care read definit rate use morgan stanley research addit sinc morgan stanley research
contain complet inform concern analyst view investor care read morgan stanley research entireti infer
content rate alon case rate research use reli upon invest advic investor decis buy sell
stock depend individu circumst investor exist hold consider
june
stock rate describ appli fundament equiti research appli debt research produc firm
disclosur purpos accord nasd nyse requir includ categori head buy hold sell alongsid
rate overweight equal-weight not-rat underweight assign rate buy hold sell stock cover
overweight equal-weight not-rat underweight equival buy hold sell repres recommend rel weight see
definit satisfi regulatori requir correspond overweight posit stock rate buy recommend correspond
equal-weight not-rat hold underweight sell recommend respect
data includ common stock adr current assign rate invest bank client compani receiv invest
bank compens last month due round decim percentag provid total column may add exactli
overweight stock total return expect exceed averag total return analyst industri industri team coverag univers
risk-adjust basi next month
equal-weight stock total return expect line averag total return analyst industri industri team coverag univers
risk-adjust basi next month
not-rat nr current analyst adequ convict stock total return rel averag total return analyst
industri industri team coverag univers risk-adjust basi next month
underweight stock total return expect averag total return analyst industri industri team coverag univers
risk-adjust basi next month
unless otherwis specifi time frame price target includ morgan stanley research month
attract analyst expect perform industri coverag univers next month attract vs relev broad
market benchmark indic
in-lin analyst expect perform industri coverag univers next month line relev broad market
benchmark indic
cautiou analyst view perform industri coverag univers next month caution vs relev broad market
benchmark indic
benchmark region follow north america latin america relev countri index latin america index europ
europ japan topix asia relev countri index sub-region index ac asia pacif ex japan index
import disclosur morgan stanley smith barney llc custom
